P/E ratio for Atara Biotherapeutics (ATRA)
P/E ratio as of June 2024 (TTM): -0.1527
According to Atara Biotherapeutics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.152698. At the end of 2022 the company had a P/E ratio of -1.47.
P/E ratio history for Atara Biotherapeutics from 2014 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -1.47 | -66.12% |
| 2021 | -4.34 | -6.89% |
| 2020 | -4.66 | 61.65% |
| 2019 | -2.88 | -56.49% |
| 2018 | -6.63 | 46.15% |
| 2017 | -4.54 | -12.15% |
| 2016 | -5.16 | -56.59% |
| 2015 | -11.9 | -23.38% |
| 2014 | -15.5 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 ImmunoGen
IMGN | -101 | 65,874.67% | 🇺🇸 USA |
 Agenus
AGEN | -16.8 | 10,917.50% | 🇺🇸 USA |
 Affimed
AFMD | -8.53 | 5,486.58% | 🇩🇪 Germany |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.